Physician profile
Yasser Ousman
NPI 1801845284
$53,120.95
in general payments reported to CMS, 2019-2025
22 companies · $613 in 2025
The $613 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $2,360 · 2021: $17K · 2022: $8,175 · 2023: $6,233 · 2024: $92.86 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,488 · Food and Beverage: $1,451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,488.00 |
| Food and Beverage | $1,450.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $51,761.16 | 2019-2025 | |
| Novo Nordisk INC | $440.05 | 2019-2025 | Wegovy, Ozempic |
| Lilly USA, LLC | $168.15 | 2019-2025 | Jardiance, Mounjaro |
| Xeris Pharmaceuticals, INC. | $127.04 | 2025 | Recorlev |
| Tandem Diabetes Care, INC. | $115.54 | 2020 | |
| Abbott Laboratories | $88.64 | 2023-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $55.29 | 2021-2025 | |
| Abbvie INC. | $48.82 | 2025 | |
| Ascendis Pharma Endocrinology INC | $37.88 | 2025 | Yorvipath |
| Averitas Pharma INC. | $26.79 | 2025 | Qutenza |
| Valeritas, INC. | $24.85 | 2019 | |
| Sequel Med Tech, LLC | $24.79 | 2025 | Twiist |
| Corcept Therapeutics | $24.37 | 2019 | |
| Antares Pharma, INC. | $23.88 | 2025 | Xyosted |
| Alexion Pharmaceuticals, INC. | $23.53 | 2025 | Strensiq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.79 | 2025 | Jardiance |
| Rhythm Pharmaceuticals, INC. | $20.27 | 2025 | Imcivree |
| Madrigal Pharmaceuticals | $19.95 | 2025 | Rezdiffra |
| Beta Bionics, INC. | $19.14 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amneal Pharmaceuticals LLC | $17.67 | 2025 | Unithroid |
| Amgen INC. | $17.06 | 2025 | Evenity |
| Novartis Pharmaceuticals Corporation | $15.29 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yasser Ousman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.